Heat Shock Protein-Based Novel Immunotherapies

BY PRAMOD K. SRIVASTAVA

Should the human experience reflect the evidence from experimental systems, the HSPs shall truly revolutionize the practice of medicine.
(38 Kb) (220 Kb)

Oxidant Stress as a Critical Determinant of Endothelial Function

BY MARC A. FORGIONE AND JOSEPH LOSCALZO

Oxidant stress, inflammation and depletion of bioavailable nitric oxide play important roles in the development and progression of endothelial dysfunction and atherothrombotic disease.
(49 Kb) (160 Kb)

From Basic Research on Neuropeptide Receptors to Clinical Benefit

BY KEVIN R. OLIVER, DALIP J.S. SIRINATHSINGHJI AND RAYMOND G. HILL

The area of neuropeptides and neuropeptide receptors continues to be an exciting field for academic and pharmaceutical research. The number of receptors is ever-increasing as new and classic technologies are applied to receptor identification, characterization and validation as drug targets.
(70 Kb) (218 Kb)

Noscapine and Analogues as Potential Chemotherapeutic Agents

BY HARISH C. JOSHI AND JUN ZHOU

Several lines of evidence show that noscapine has a clear potential to be a potent antitumor agent.
(24 Kb) (82 Kb)

NME Digest

Eighty-nine New Molecular Entities are reported this month:
(R)-HI-509, (R)-HI-510, (R)-HI-511, (R)-HI-512, (R)-HI-513, (S)-CPW-399, 5-ASA-Cys, 5-FdU-NOAC, ABT-963, AF-2785, AN-37124 (LY-374973), BCH-13520, CGS-33090A, CHAP-31, CJ-13610, CP-463755, CRL-8256, DA-7686, DAP-40, DAP-42, DAP-64, DAP-75, DJS-631, DJS-811, E-6060, GW-471552, GW-471558, GW-506540, GW-531920, GW-560849, HEP-187, JE-2178, JE-2179, KF-21652, KF-24345, LF-18-1505T, MAG-283, nitroparacetamol, NNC-21-0300, NNC-53-0016, OC-229-648, Org-25435, PD-0007258, PD-0084430, Ro-26-9228, S-34324, SB-331750, SB-357114, ST-1480, ST-1481, TA-510, TNF-484, TQX-173, TTL-1, TTL-3, VRC-3125, VRC-322, VRC-3251, VRC-3324, VRC-3343, VRC-3375, VRC-3375, VRC-3375, VRC-3406, VRC-3054, VRC-3055, VRC-3488, VRC-3599, VRC-3816, VRC-3839, VRC-3881, VRC-3896, VRC-3997, VRC-408, WAY-140424, WQ-2944, WQ-3402, Y-40111, YLL-224 and YM-53601.
(61 Kb) (142 Kb)

New Product Intros

Aminolevulinic acid hydrochloride; arsenic trioxide; drospirenone; esomeprazole magnesium; medroxyprogesterone acetate/estradiol cypionate; methylphenidate hydrochloride; mitoxantrone hydrochloride (new indication); and zoledronic acid.
(9 Kb) (59 Kb)

Molecule of the Month

V-Glycopeptide.
(6 Kb) (53 Kb)

MEETING REPORTS

Defining the Role of COX-2 Inhibitors in Inflammatory and Other Diseases

BY JACK BOTTING

The improved safety profile of COX-2­selective inhibitors in the treatment of pathological conditions and the possible significance of the COX-2 enzyme in the etiology of cancers and Alzheimer's disease were discussed at the William Harvey Research Conference held in Porto, Portugal, October 2­3, 2000.
(43 Kb) (225 Kb)

Angiogenesis and Cancer: From Basic Mechanisms to Therapeutic Applications

BY PATRICIA M. FERNANDEZ

Highlights of the AACR Special Conference on Angiogenesis and Cancer, held October 11­15, 2000, in Traverse City, Michigan, U.S.A.
(59 Kb) (142 Kb)